As Omicron-specific boosters are in the news, BioNTech to expand German site workforce by 200 employees
BioNTech has added about 200 jobs to its Marburg, Germany manufacturing site since it took it over from Novartis in 2020. This year, it will add another 250, as demand for Covid-19 boosters has led to calls for an omicron-specific vaccine in adults.
Currently, there are around 500 employees at the site, which is north of Frankfurt. The boost is expected to cost around €50 million, or $56.5 million, and will include the addition of office spaces in anticipation of future growth, the company said. The Marburg site has supplied 1.2 billion Covid-19 vaccine doses to the world so far, and a total of 4 billion doses are expected to be doled out by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
